US2009270446A1PendingUtilityA1

Diamine derivatives

67
Assignee: DAIICHI SEIYAKU COPriority: Jun 20, 2001Filed: Mar 6, 2009Published: Oct 29, 2009
Est. expiryJun 20, 2021(expired)· nominal 20-yr term from priority
Inventors:Toshiharu OhtaSatoshi KomoriyaToshiharu YoshinoKouichi UotoYumi NakamotoHiroyuki NaitoAkiyoshi MochizukiTsutomu NagataHideyuki KannoNoriyasu HaginoyaKenji YoshikawaMasatoshi NagamochiSyozo KobayashiMakoto Ono
A61P 9/00A61P 43/00A61P 7/02A61P 7/00A61P 9/10A61P 29/00C07K 5/0827A61K 31/4365C07D 209/42A61K 31/444C07D 513/14A61K 31/4439C07D 417/14C07D 495/04A61K 31/437C07D 498/04A61K 31/428C07D 417/12C07D 401/14A61K 31/4545C07D 487/04A61K 31/429C07D 513/04C07D 401/12A61K 31/454C07K 5/06191
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to diamine compounds which inhibit activated blood coagulation factor X and exhibit an anticoagulant effect and there uses for treating various diseases based on thromboembolism.

Claims

exact text as granted — not AI-modified
1 . A composition comprising a pharmaceutically acceptable carrier and N 1 -(5-chloropyridin-2-yl)N 2 -(4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetralhydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide, represented by Formula (I), or a salt thereof: 
       
         
           
           
               
               
           
         
       
     
     
         2 . A composition comprising a pharmaceutically acceptable carrier and N 1 -(5-chloropyridin-2-yl)-N 2 -(4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide p-toluenesulfonate, represented by Formula (II): 
       
         
           
           
               
               
           
         
       
     
     
         3 . A composition comprising a pharmaceLitically acceptable carrier and N 1 -(5-chloropyridin-2-yl)-N 2 -(4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide p-toluenesulfonate monohydrate, represented by Formula (III): 
       
         
           
           
               
               
           
         
       
     
     
         4 . A composition comprising a pharmaceutically acceptable carrier and N 1 -(5-chloropyridin-2-yl)-N 2 -((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide, represented by Formula (IV), or a salt thereof: 
       
         
           
           
               
               
           
         
       
     
     
         5 . A composition comprising a pharmaceutically acceptable carrier and N 1 -(5-chloropyridin-2-yl)-N 2 -((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino cyclohexyl)ethanediamide p-toluenesulfonate, represented by Formula (V): 
       
         
           
           
               
               
           
         
       
     
     
         6 . A composition comprising a pharmaceutically acceptable carrier and N 1 -(5-chloropyridin-2-yl)-N 2 -((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide p-toluenesulfonate monohydrate, represented by Formula (VI):

Join the waitlist — get patent alerts

Track US2009270446A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.